Kornimate/medical-research-clean huggingface dataset:
an observational study to assess malnutrition risk

Conditions: Malnutrition

Summary: this is a prospective, observational study for assessing malnutrition risk and its characteristics among children aged 1 to 5 living in under-resourced communities in colombia. there is also a qualitative component that seeks to gain caregiver, community health worker (chw), public health professional (php), and non-for-profit organization (ngo) insights related to malnutrition risk.


Eligibility criteria:
quantitative inclusion criteria: * children aged 1-5 years * children's legal guardian agrees to participate in the study * full term pregnancy * residence in study area attending children international (ngo) centers quantitative exclusion criteria: * children who have current medical conditions requiring hospitalization: gastrointestinal tract infections or inflammatory bowel disease; active tuberculosis; acute hepatitis b or c; human immunodeficiency virus or malignancy; cystic fibrosis; immunodeficiency syndromes, congenital abnormalities of the respiratory tract, such as lung and respiratory cilia; an unsuspected foreign body in the respiratory tract; asthma; and known metabolic disorders, renal impairment, or rheumatic diseases and diabetes, * congenital condition * children with disabilities such as cerebral palsy, autism spectrum disorder, neurodegenerative disorders * children with chronic or acute infections e.g. hiv, malaria * children who are taking medications or other agents that could potentially affect body weight, including diuretics, appetite stimulants, steroids, and growth hormones. * children already enrolled in a nutrition program/intervention that includes a supplement qualitative inclusion criteria: * ngo staff taking part in nutrition screenings * caregivers taking part in nutrition screenings as part of this study * community health workers (chw) working with pediatric malnutrition risk * public health professionals (php) working with pediatric malnutrition risk * agrees to participate in focus group/survey qualitative exclusion criteria: * not involved in the implementation of the study * not involved in working with pediatric malnutrition risk * declines participation in focus group/survey
opioid rotation versus combination for chronic uncontrolled cancer pain

Conditions: Advanced Solid Cancers

Summary: for cancer patients with inadequate pain relief, a switch to an alternative opioid is the preferred option for symptomatic improvement. however, multiple opioids are often simultaneously administered for anecdotal reasons. the present study isdesigned to assess the analgesic profiles of two different strategies in chronic cancer pain: the opioid rotation from oxycodone to transdermal fentanyl and the combination of oral oxycodone and transdermal fentanyl.

patients with uncontrolled cancer pain despite treatment of oral morphine equivalent ≥100 mg/d will be randomly assigned to oral opioids to transdermal fentanyl (rotation group) or oral oxycodone plus fentanyl (combination group). patients answer a questionnaire that included pain severity (0 to 10) and interference items at baseline and after one week. primary outcomes are change in pain score and treatment success.

Eligibility criteria:
inclusion criteria: * chronic uncontrolled pain that required stronger opioid therapy than they have been taking * histologically confirmed solid cancer * aged over 18 years * admitted in a palliative cancer care unit exclusion criteria: * uspected to have narcotic abuse, clinically relevant co2 retention or had an active skin disease * inability to swallow oral medication, and impaired sensory or cognitive function * patients who had an active infection, uncontrolled central nervous system involvement, or on antitumor therapy of any kind

Keywords: pain
necklace-shaped sensor for non-invasive monitoring of stroke volume and cardiac output

Conditions: Heart Failure

Summary: study will compare measurements made with necklace device for stroke volume/cardiac output with values from a fda-approved reference device. the gold standard that will be used is cardiac mri. subjects will be measured with both the necklace, reference device, and the cardiac mri. values calculated by the cardiac mri analysis will be compared with the reference device and the necklace.

study will compare measurements made with necklace device for stroke volume/cardiac output with values from a fda-approved reference device. the gold standard that will be used is cardiac mri. subjects will be measured with both the necklace, reference device, and the cardiac mri. values calculated by the cardiac mri analysis will be compared with the reference device and the necklace. the cardiac mri will be received \~1-4 days after the measurement is completed. the data will be compared with data collected from the necklace and the reference device during the study.

Eligibility criteria:
inclusion criteria: * must be able to undergo cardiac mri exclusion criteria: * sensitivity to electrodes
performance indicators and patient experience in 7g and 10g vacuum-assisted excision of probably benign breast lesions

Conditions: Breast Diseases

Summary: the purpose of this study is to assess how the needle size 7g vs 10g affects performance indicators and patient experience in vacuum-assisted excision (vae) of probably benign breast lesions

after being informed about the study and potential risks, all patients giving written informed consent will have a vae procedure to remove their breast lesion and will be randomised to either 7g or 10g needle size. after completion of the procedure, the patients fill out a questionnaire to collect data on their experience. the radiologist performing the procedure fills out a form collecting procedural performance indicators.

Eligibility criteria:
inclusion criteria: * biopsy-verified probably benign breast lesion less than 20 mm size * biopsy-verified benign breast lesion less than 30 mm size * screen-detected group of microcalcifications under 10 mm size exclusion criteria: * age less than 18 years of age * inability to understand the meaning of informed consent * pregnancy * breast-feeding

Keywords: vacuum-assisted excision breast minimally invasive procedure needle size
the role of satiety in the effect of portion size on intake

Conditions: Feeding Behavior

Summary: the study uses a crossover design in which the portion size of food is varied at each meal. across four test meals, subjects will be served four different portions of food, and intake will be determined from pre- and post-meal food weights. the first visit will be a screening visit, at which subjects will complete the consent form, have their height and weight measured, and rate the taste of the study food. test meals will be scheduled once a week for four weeks. at visits 2-5, subjects will eat lunch and rate characteristics of the meal. at visit 6, subjects will complete various questionnaires. the objective of this study is to determine whether any individual characteristics related to satiety influence the effect of portion size on intake.


Eligibility criteria:
inclusion criteria: * be willing and able to travel to penn state university park campus weekly for meals * be a man or woman 18 - 60 years old * regularly eat 3 meals/day * be willing to avoid alcohol the day before and during test days * have a body mass index between 18.0 and 35.0 kg/m-squared * be willing to refrain from eating after 10 pm the evening before test sessions exclusion criteria: * a smoker * an athlete in training * pregnant or breastfeeding at the time of screening * have taken prescription or non-prescription drugs that may affect appetite or food intake within the last 3 months * dislike or be unable to eat the test foods (because of allergies, intolerance, or dietary restrictions) * currently dieting to gain or lose weight * have a health condition that affects appetite * have participated in a similar study in our lab in the past year

Keywords: obesity, eating behavior, food, nutrition
a study of a potential oral treatment to prevent covid-19 in adults who are exposed to household member(s) with a confirmed symptomatic covid-19 infection

Conditions: COVID-19

Summary: the purpose of this clinical trial is to learn whether the study medicine prevent symptoms of covid-19 in adults who have been exposed to household member(s) with a confirmed symptomatic covid-19 infection. all participants in the study will receive treatment for covid-19 as needed, based on their regular doctor's recommendation. two-thirds of participants will also receive two study medicines (pf-07321332 and ritonavir) by mouth twice a day for either five or ten days. we will compare the experiences of people receiving the study medicines to those of the people who do not. this will help us determine if the study medicines are safe and effective


Eligibility criteria:
inclusion criteria: * participants who have a negative screening sars-cov-2 rapid antigen test result and who are asymptomatic household contacts with exposure within 96 hours to an individual who is symptomatic and recently tested positive for sars cov-2. * fertile participants must agree to use a highly effective method of contraception exclusion criteria: * history of sars-cov-2 infection in the past 6 months * experiencing measured fever (documented temperature \>38˚c or 100.4˚f) or other signs or symptoms consistent with covid-19 * known medical history of active liver disease * chronic kidney disease or have known moderate to severe renal impairment. * known human immunodeficiency virus (hiv) infection with viral load \> 400 copies/ml within the last 6 months or taking prohibited medications for hiv treatment * suspected or confirmed concurrent active systemic infection * active cancer requiring treatment with prohibited medication. * current or expected use of any medications or substances that are highly dependent on cytochrome p450 3a4 (cyp3a4) for clearance or are strong inducers of cyp3a4 * has received approved, authorized, or investigational anti-sars-cov-2 mab, convalescent plasma, other drugs for treatment of covid-19, or other anti-sars-cov-2 biologic products within 6 months of screening * has received any sars-cov-2 vaccine within 6 months prior to screening or is expected to receive a sars-cov-2 vaccine or other approved, authorized, or investigational postexposure prophylaxis treatments through day 38. * participating in another interventional clinical study with an investigational compound or device, including those for covid-19 * known or prior participation in this trial or another trial involving pf-07321332. * females who are pregnant or breastfeeding.

Keywords: severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
rivastigmine for intensive care unit (icu) delirium

Conditions: Delirium

Summary: delirium in intensive care (ic) patients is a frequent disorder. the aim of this study is to investigate whether treatment of delirium in the icu with rivastigmine added to haloperidol shortens the duration of delirium in comparison to placebo added to the treatment with haloperidol.

objective: to study whether rivastigmine added to treatment with haloperidol shortens the duration of delirium in icu patients and reduces costs. study design: multicentre, double-blind, randomized controlled trial. study population: consecutive adult icu patients with delirium according to the cam-icu. intervention: increasing dosage of rivastigmine or placebo as add-on medication. primary study parameters: duration of delirium. secondary study parameters: delirium severity, length of icu and hospital stay, functional status and mortality after 3 months. sample size: 440 patients will be included. economic evaluation: includes a comparison of direct and indirect medical costs. nature and extent of the burden and risks associated with participation, benefit and group relatedness: burden: questionnaires (duration: 30 minutes). risk: possible exposure to drug not indicated for the disorder. benefit: possible treatment with according to experts possible beneficial drug. consideration: the investigators of this study believe that the burden and risk do not exceed the expected benefit.

Eligibility criteria:
inclusion criteria: * 18 years or older * positive cam-icu exclusion criteria: * known allergy to rivastigmine * unable to receive enteric medication * pregnant or lactating * renal replacement therapy * hepatic encephalopathy * second or third degree atrioventricular block * uncertainty about diagnosis delirium and no confirmation by neurologist, psychiatrist or geriatrician * parkinson's disease. * lewy body dementia. * ecg qt interval above 500 msec. * no informed consent

Keywords: delirium confusion
study of seroprevalence vis-à-vis sars-cov2 and correlation with clinical forms of covid-19 in patients followed in pneumology in the cluster area of the grand-est region (strasbourg university hospital)

Conditions: Covid-19

Summary: seroprevalence vis-à-vis sars-cov2 and correlation with clinical forms of covid-19 in patients followed in pulmonology in the cluster area of the grand-est region.


Eligibility criteria:
inclusion criteria: * man or woman from 18 years old and without upper age limit * patient followed in pulmonology at strasbourg university hospital * patient presenting at least one of the following pathologies: 1. severe persistent asthma (200 patients) 2. chest cancer that is active or has received treatment within a period of less than one year (300 patients) 3. history of lung transplantation performed before the start of the epidemic (02/29/2020) (300 patients) 4. idiopathic or other diffuse interstitial lung disease, sarcoidosis or vasculitis (70 patients) 5. pulmonary arterial hypertension (pah) (group 1 of the international classification) any cause or chronic thromboembolic pah (group 4): (60 patients) 6. severe copd in the respiratory failure stage (150 patients) * subject affiliated to a social health insurance protection scheme * subject able to understand the objectives of the research * subject having signed an informed consent exclusion criteria: * inability to provide informed information about the subject (subject in an emergency situation, difficulty in understanding the subject, etc.) * subject under safeguard of justice * subject under guardianship or guardianship
physical therapy on quality of life and function following vaginal surgery reconstructive surgery

Conditions: Quality of Life; Pelvic Floor Distress and Impact Scores; Sexual Function Scores

Summary: i) the primary objective of this study is to determine if physical therapy improves postoperative quality of life in participants following vaginal reconstructive surgery for pelvic organ prolapse and urinary incontinence. ii) secondary objectives include: 1. comparing pelvic floor symptoms (urinary symptoms, defecatory symptoms and prolapse symptoms) in participants undergoing physical therapy compared to standard postoperative care 2. comparing sexual function in participants undergoing physical therapy compared to standard postoperative care; 3. comparing postoperative pain scales, and activity assessment in participants undergoing physical therapy compared to standard postoperative care; 4. comparing pelvic floor strength and pelvic organ prolapse quantification (popq)(12) in participants undergoing physical therapy compared to standard postoperative care.

this is a single center randomized controlled trial assessing quality of life in participants following vaginal surgery receiving physical therapy compared to standard postoperative care. patients will be under care of the physicians of the division of urogynecology and reconstructive pelvic surgery. all physicians are board certified, fellowship trained urogynecologists.

Eligibility criteria:
inclusion criteria: * vaginal reconstructive surgery for prolapse * age of at least 18 years * willing to comply with physical therapy exclusion criteria: * i. use of mesh/graft material during the prolapse repair * ii. abdominal or laparoscopic prolapse repair * iii.current genitourinary fistula or urethral diverticulum * iv. contraindication to surgery * v. unable to comply with physical therapy or office visits * vi. preexisting neurological condition * vii.concurrent surgery for fecal incontinence

Keywords: physical therapy pelvic prolapse incontinence quality of life
dabigatran for the adjunctive treatment of staphylococcus aureus bacteremia

Conditions: Staphylococcus Aureus Endocarditis; Staphylococcus Aureus Septicemia; Staphylococcus Aureus Bacteremia; Staphylococcus Aureus Bloodstream Infection; S. Aureus Bacteremia; S. Aureus Bloodstream Infection

Summary: this is an open-label randomized controlled trial which will enroll patients with s. aureus bacteremia who are already taking oral anticoagulant medications (apixaban, edoxaban, or rivaroxaban) for an approved indication (stroke prevention in atrial fibrillation, prevention or treatment of venous thromboembolism). we will randomize patients to continue their existing medication or change to another medication (dabigatran) which is approved for the original indication. dabigatran is approved in many countries for the treatment or prevention of venous thromboembolism or preventing stroke in atrial fibrillation. unlike the other medications listed above, dabigatran seems to have activity against s. aureus in the test tube, in animal models, and in a smaller randomized controlled trial. we wish to determine if changing to dabigratran will improve outcomes in s. aureus bacteremia in people who otherwise would have a reason to be taking it. this study is an approved sub-study of the staphylococcus aureus network adaptive platform (snap) trial (nct05137119). if positive, this study will support a second rct in people who do not currently have an indication for anticoagulation.


Eligibility criteria:
the participant must meet all inclusion and exclusion criteria for the snap platform (nct05137119) and also the following inclusion and exclusion criteria: inclusion criteria: * patient is taking an oral xa inhibitor for: stroke prevention in atrial fibrillation, treatment or secondary prevention of deep venous thrombosis or pulmonary embolism, prevention of vte in patients who have undergone elective total hip or total knee replacement surgery provided there are 30 or more days of planned treatment remaining at the time of enrolment. exclusion criteria: * active bleeding (allowing up to 5 days from the index blood culture to randomize in the event anti-thrombotic therapy is resumed) * anticipated major cardiac surgery, neurosurgery, or spine surgery within the next 3 days * pregnancy * known use of dabigatran within last month * allergy to dabigatran * concomitant use of amiodarone, ketoconazole, rifampin, verapamil, clopidogrel, prasugrel, or ticagrelor * egfr \< 30ml/minute calculated by cockcroft-gault equation using adjusted weight \[if acute kidney injury can allow for up to 5 days from index blood culture to allow for recovery\] * off label use (e.g., metallic mechanical heart valve, left ventricular thrombus, antiphospholipid antibody syndrome)

Keywords: s. aureus bacteremia s. aureus bloodstream infection s. aureus endocarditis dabigatran edoxaban rivaroxaban apixaban
goals of sexual function in prostate cancer survivors and their partners after cancer treatment

Conditions: Prostate Cancer

Summary: rationale: gathering information about survivors of prostate cancer and their partners may help doctors learn more about the goals for sexual functioning after cancer treatment. purpose: this clinical trial is studying the goals of sexual functioning in prostate cancer survivors and their partners after cancer treatment.

detailed descriptionobjectives: i. to collect data on the goals of sexual functioning among prostate cancer survivors and their partners following cancer treatment in order to identify specific components of interventions for future grant submissions on the psychosexual needs of prostate cancer survivors. outline: patients and their partners complete surveys. sexual function of men is assessed by the international index of erectile function; sexual function of women is assessed by the female sexual function index.

Eligibility criteria:
inclusion criteria: * prostate cancer survivors who are: willing and able to provide informed consent; able to read, write, and speak english; married or are in married-like relationship; completed radiation or surgery for their prostate cancer 6 months to 5 years ago * partners of prostate cancer survivors must be: willing and able to provide informed consent; able to read, write, and speak english exclusion criteria: * prostate cancer survivors will be excluded if they have undergone androgen deprivation therapy within the past 6 months and if their partners refuse to participate
iron fortified food to improve japanese encephalitis and typhoid fever vaccine immunogenicity

Conditions: Iron Deficiency Anemia

Summary: iron deficiency (id) anaemia (ida) is a global public health problem, with the highest prevalence in africa and in south-east asia. while immunization programs have achieved high global coverage, vaccines often underperform in low- and middle-income countries (lmic). the cause remains uncertain, but undernutrition, including id, likely plays a role. our recent in vitro and in vivo studies have shown the importance of iron status in adaptive immunity and vaccine response. hypoferremia blunted t cell, b cell, and neutralizing antibody responses to influenza virus infection in mice, allowing the virus to persist. iron deficient anaemic kenyan women receiving intravenous iron at time of vaccination had a better immune response to the first dose of the chadox coronavirus 19 (covid-19) vaccine and yellow fever vaccine. japanese encephalitis and typhoid fever are endemic in thailand. vaccines are available but show variable efficacy. whether id impairs adult vaccine response to the live attenuated japanese encephalitis (je) and the typhoid vi polysaccharide (vi-ps) vaccine and whether iron repletion via iron fortification improves vaccine response is uncertain. the objective of this study is to assess whether ida in thai women impairs immune response to the je and the typhoid vi-ps vaccine and whether fortification iron improves their response. in this double-blind randomized controlled trial, ida women will be assigned to two study groups: group 1 (fortification group) will receive iron-fortified biscuits (15mg iron as ferrous fumarate) for 56 days; group 2 (control group) will receive non-fortified biscuits for 56 days. all women will receive live attenuated je and typhoid vi-ps vaccine on study day 28. vaccine response will be measured 28 days after vaccination (on day 56) in both groups.


Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the trial. * female aged 18-49 years. * diagnosed with anaemia (i.e. hemoglobin (hb) concentration \ 40 µmol/mol) * anticipated residence in the area for the study duration exclusion criteria: * pregnant (confirmed by rapid test during screening and at time of vaccination), lactating or planning pregnancy during the trial. * blood transfusion or intravenous iron treatment within 4 months of study start * major chronic infectious disease (e.g., tuberculosis, hiv+, hepatitis) * major chronic non-infectious disease (e.g., type 1 or 2 diabetes, cancer) * treatment with supplemental iron two weeks prior to enrolment * je or typhoid vaccine within the past two years